BioNTech (NASDAQ:BNTX) Shares Up 6.1%

BioNTech SE (NASDAQ:BNTX)’s share price shot up 6.1% on Wednesday . The company traded as high as $98.68 and last traded at $97.71. 657,251 shares traded hands during mid-day trading, an increase of 4% from the average session volume of 631,224 shares. The stock had previously closed at $92.07.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. HC Wainwright upped their price objective on BioNTech from $107.00 to $113.00 and gave the stock a “buy” rating in a report on Wednesday, May 8th. The Goldman Sachs Group cut their price target on shares of BioNTech from $113.00 to $100.00 and set a “neutral” rating for the company in a report on Wednesday, February 28th. Evercore ISI began coverage on shares of BioNTech in a report on Tuesday, May 14th. They set an “inline” rating and a $100.00 price objective on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $171.00 target price on shares of BioNTech in a report on Thursday, March 21st. Finally, BMO Capital Markets reduced their price target on shares of BioNTech from $123.00 to $122.00 and set an “outperform” rating for the company in a research report on Tuesday, May 7th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, BioNTech presently has an average rating of “Hold” and an average price target of $111.70.

BioNTech Trading Up 8.2 %

The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.16 and a current ratio of 11.38. The business has a fifty day simple moving average of $90.54 and a 200 day simple moving average of $95.84. The stock has a market cap of $23.69 billion, a price-to-earnings ratio of 194.84 and a beta of 0.25.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Wednesday, March 20th. The company reported $2.05 EPS for the quarter, missing analysts’ consensus estimates of $2.64 by ($0.59). BioNTech had a net margin of 4.01% and a return on equity of 0.55%. The company had revenue of $1.59 billion for the quarter, compared to analyst estimates of $2.04 billion. As a group, equities analysts anticipate that BioNTech SE will post -1.99 EPS for the current year.

Hedge Funds Weigh In On BioNTech

A number of institutional investors have recently modified their holdings of BNTX. Cary Street Partners Investment Advisory LLC grew its stake in BioNTech by 6.9% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 1,711 shares of the company’s stock worth $186,000 after acquiring an additional 111 shares during the period. Sectoral Asset Management Inc. grew its position in shares of BioNTech by 3.5% in the third quarter. Sectoral Asset Management Inc. now owns 3,445 shares of the company’s stock valued at $374,000 after purchasing an additional 116 shares during the period. Dynamic Technology Lab Private Ltd increased its stake in BioNTech by 2.5% in the fourth quarter. Dynamic Technology Lab Private Ltd now owns 4,666 shares of the company’s stock valued at $492,000 after purchasing an additional 116 shares during the last quarter. Covestor Ltd lifted its position in BioNTech by 47.2% during the first quarter. Covestor Ltd now owns 415 shares of the company’s stock worth $38,000 after buying an additional 133 shares during the period. Finally, Cambridge Investment Research Advisors Inc. boosted its stake in BioNTech by 3.9% in the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 3,980 shares of the company’s stock worth $432,000 after buying an additional 148 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.